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ABSTRACT
canSAR (http://cansar.icr.ac.uk) is a public, freely
available, integrative translational research and
drug discovery knowlegebase. canSAR informs re-
searchers to help solve key bottlenecks in can-
cer translation and drug discovery. It integrates ge-
nomic, protein, pharmacological, drug and chemical
data with structural biology, protein networks and
unique, comprehensive and orthogonal ‘druggabil-
ity’ assessments. canSAR is widely used interna-
tionally by academia and industry. Here we describe
major enhancements to canSAR including new and
expanded data. We also describe the first compo-
nents of canSARblack––an advanced, responsive,
multi-device compatible redesign of canSAR with a
question-led interface.
INTRODUCTION
Translating biological discoveries into the clinic requires the
analysis and support of vast amountsmultidisciplinary data
that is generally difficult to integrate andmaintain. canSAR
(http://cansar.icr.ac.uk) (1–3) is a freely available, multidis-
ciplinary knowledgebase developed to bring together bil-
lions of experimental datapoints and information in or-
der to empower translational research and drug discov-
ery. canSAR not only collates, but also integrates inter-
disciplinary data including genomic, transcriptomic, pro-
tein, pathway, chemical, pharmacological and 3D structural
data. Moreover, canSAR is also the world’s most compre-
hensive druggability assessment resource. canSAR provides
a powerful, unique and user-friendly portal to help gener-
ate and test hypotheses and, in particular to support sci-
entific decision-making in drug discovery both before and
after target selection. While some of the data in canSAR,
in particular genomic and functional biological screen data,
are specific to cancer, much of the data within it are relevant
to other diseases.
To our knowledge, canSAR is the first and remains the
largest, most comprehensive, multidisciplinary resource to
support translational cancer research and drug discovery.
Since its first release in 2011, canSAR has been used by over
200,000 unique visitors from 200 countries (source: Google
Analytics, excluding IP addresses from our home institute).
To date, canSAR and its methodologies has been cited by
well over three hundred peer-reviewed publications.
Here, we describe themost up to date version of canSAR,
canSAR v4.0. In addition, we describe the first compo-
nents of canSARblack ––the ‘next generation’ of canSAR,
comprising an advanced, responsive, multi-device compat-
ible redesign of canSAR with a question-led user interface.
canSARblack is named after the pharmacologist Sir James
Black, an early exponent of developing drugs against a spe-
cific molecular target. Table 1 summarizes key differences
between the previous v3 version and the current version of
canSAR.
DATA CONTENT AND GROWTH
canSAR v4.0 contains updates to many key datasets, to-
gether with integration of new resources. Gene expression
and mutational data have been updated using The Can-
cer Genome Atlas (TCGA, GDCVersion 11), including 2.8
million protein coding mutational events in cancer patients
of which 425,000 are from cancer metastases (4). Where
matched normal tissue profiling is available, these data are
also curated for comparison. Gene expression data are sim-
ilarly curated from TCGA. In order to provide researchers
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Table 1. Comparison of data and features between v3 and current version
Feature canSAR v3 canSAR v4/Black
DATA
Protein structures >111 000 protein structures for c297 000
individual PDB chains
>140 000 protein structures and >390,000
individual PDB chains
Data on small molecules Over one million, bioactive, small molecule
drugs and compounds corresponding to >8
million pharmacological bioactivities
Integration of ChEMBL 24 and canSAR-curated
small molecules, totaling over 1.9 million drugs
and chemical compounds and >15 million
pharmacological bioactivities
Curated protein-protein interaction network Network of c13 000 proteins Network of c14 000 proteins
Information on clinical trials Integration of over 179 000 clinical trial
summaries
Integration of over 228 000 trial summaries
Integration of expert-curated assessment of
chemical probes
- Full integration of ProbeMiner
Druggability assessments of protein complexes
and ligandable interface cavities
- Annotation of >207 000 biological complexes and
identification of 77 000 ligandable interface cavities
Normal tissue gene expression reference - Approximately 10 000 samples from GTEx
Post-translational modification data - Curated data from Phosphosite
Cancer association information - Novel analysis of each gene’s association with
different cancer types based on clinical studies,
patient mutation, copy number alteration, gene
expression and cell line dependency data.
Deeper annotation of patient omic data - Pathology- and clinical based staging curated,
omic profiles organized into the different stages
FUNCTIONALITY
Search features Basic search facility New responsive Elastic Search-based search engine
Druggability view V3 Table with summary of structure-based
druggability for individual chains
Completely re-implemented, multilayered
druggability and ligandability. Users can explore
all alternative druggability assessments. For
structure-based druggability, expert users can drill
deeply into the analysis to individual cavities on
individual structures.
Cancer association view - Visualization of key cancer-type association. Users
can explore details of associations based on clinical
studies, patient omics and cell line dependencies
with normal tissue reference points, canSAR now addition-
ally integrates profiling data on ca. 10,000 samples from the
GTEx project (https://gtexportal.org/ (5)).
canSAR fully incorporates and integrates a number of
medicinal chemistry databases, as well as an increasing
number of canSAR-curated small molecule compounds.
Collectively, these provide canSAR with over 1.9 million
drugs and chemical compounds and >15 million pharma-
cological bioactivity data points. canSAR continues to up-
date its content weekly, including curation and analysis of
3D protein structure data. It currently holds >140 000 pro-
tein structures (>390 000 individual PDB chains).
To enable more detailed investigation of proteins,
canSAR is compiling and curating posttranslational modi-
fication data from public resource and the literature, includ-
ing residue-level phosphorylation data from Phosphosite
(6). canSAR now fully integrates these data to enable en-
hancements of directional protein-protein interaction data,
such as kinases and their substrates. Furthermore, this in-
formation can help researchers select potential target en-
gagement and mechanistic biomarkers for kinase activity in
the laboratory.
We increased the curated canSAR protein-protein in-
teractome to cover almost 14 000 proteins. Additionally,
canSAR now contains details of over 228,000 clinical trials
from ClinicalTrials.gov, which are linked to disease, protein
targets and compounds.
ENHANCEMENTS AND NEW DATA IN DRUGGABIL-
ITY ASSESSMENTS AND ANNOTATION
canSAR provides a comprehensive suite of sophisti-
cated, orthogonal druggability assessment methodolo-
gies utilizing machine learning and AI predictions devel-
oped by the team (2,7,8). We identify and predict the
‘ligandability’––the propensity of a protein to bind a drug-
like small molecule––of proteins with known 3D structure
(2). As mentioned above, the canSAR 3D pipeline is up-
dated weekly and to date has identified and analysed >3
777 000 cavities on >140 000 protein structures (>390 000
PDB chains). New to canSAR v4.0, we now identify and
annotate biologically relevant structural complexes in the
PDB (9), and identify potential ligandable cavities at their
interfaces.We have analysed>207,000 biological complexes
and identified 77 000 ligandable interface cavities.
Additionally, we include prevalent somatic mutations
and sequence conservation across families to annotate po-
tentially druggable non-primary sites, that may lead to the
identification of important, pharmacologically accessible
allosteric or second sites.
To allow orthogonal assessment of potential targets, and
also enable the assessment of targets that do not have a 3D
structure available, we continue to enhance and update the
non-3D protein structure-dependent druggability assess-
ments.We have updated the chemistry-based assessment (7)
which evaluates targets based on the chemical landscape of
the target itself and its protein family. Compounds active
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against either the target in question or its homologues are
assessed for their potency, ligand-efficiency, diversity and
drug-likeness, among other parameters. In canSAR v4.0,
we provide chemistry-based assessment for >8300 human
proteins. canSAR also includes an AI-based assessment of
‘drug target-likeness’ that is based purely on the protein’s
behaviours in cellular networks (8). This assessment exam-
ines whether a protein exhibits behaviours (in terms of its
short and long-range protein-protein interaction patterns)
characteristic of target of cancer drugs and/or a target of
drugs fromnon-cancer therapeutic areas. canSARnow con-
tains these assessments for almost 14 000 human proteins.
Together, these unique data make canSAR the largest
public resource for druggability assessment and provide a
powerful enabler for target selection and validation for drug
discovery. Examples of how these data can be viewed are
shown in Figure 1.
ENHANCED CURATION OF PUBLIC DATA FOR MORE
MEANINGFUL INTERPRETATION
Integrating interdisciplinary data into canSAR has already
proved to be very useful for canSAR users who can exam-
ine clinical genomics, pharmacological data and biophys-
ical data on one target protein at a time. However, in or-
der to further empower researchers in generating biological
hypotheses and devising their next experiments, continuing
deeper curation of these integrated data is essential. In addi-
tion to the curation described in previous canSAR publica-
tions (1–3), we now deeply curate and re-analyse all gene
expression data from TCGA and GTEx to enable cross-
platform and cross-study comparisons.
In order to provide moremeaningful annotation, we have
curated and standardised staging systems for the majority
of samples in canSAR. We primarily adopted the TCGA
pathology-based system where available and appropriate.
Both clinical and surgical-based information on the cancer
at the date the biopsy was taken were combined. This allows
tracing the aberrations of genes not just between studies and
normal tissue, but also between different stages of progres-
sion of the disease (Figure 2). In some cases, the use of the
clinical staging information was less relevant, in which case
we adopted the most appropriate staging system (e.g. Glee-
son for prostate cancer). In each study, we map the molec-
ular profiling data to these stages and provide the user with
the precise staging system used.
Another important enabler for researchers is the use of
chemical probes. Probe Miner™ (probeminer.icr.ac.uk (10))
is a large-scale, objective chemical probe assessment plat-
form which applies assessment of probe fitness factors to
all compounds in canSAR, and ranks these compounds for
their suitability to be used as chemical probes for any spe-
cific human protein. Probe Miner was developed to be a
live-data-responsive and automated probe assessment tool,
to complement the expert annotation of chemical probes
provided by the Chemical Probes Portal (chemicalprobes.
org). Between the two resources, researchers can select the
most appropriate probes for their research. canSAR now
contains the probe annotations from both resources and
provides links to them, where available, for each human pro-
tein.
canSAR BLACK NEW INTUITIVE INTERFACE FOR
TRANSLATIONAL RESEARCH
canSAR is evolving and increasingly focusing on user ex-
perience and key capabilities. canSARblack is a new inter-
face to canSAR, being designed with the improving user
experience as a central driver. It provides a more advanced
interface with responsive, interactive visualizations, filter-
ing and navigation capabilities. canSARblack works across
all platforms and is mobile device-compatible and screen-
resolution adaptive. The main interface development tool
is a javascript framework, Vue.js (https://vuejs.org/) using
Vuex pattern (https://vuex.vuejs.org/).
Over the next year, all canSAR functionality will migrate
to the canSARblack interface.Meanwhile, in response to user
feedback, we have focused on the development a better
search facility and a new version of the Target Synopsis. A
key paradigm change in canSARblack is the provision of data
as answers to key translational questions such as: what is the
evidence that a target might be suitable for drug discovery?;
what is the evidence of a target’s association with a partic-
ular cancer?; what are the key experimental tools available
to mechanistically explore a target? Moreover, canSARblack
provides multi-layered summaries. The first layer is a sim-
ple visual summary of the key information. Users can then
navigate into increasingly complex visualizations and data
analyses in accordance with their interest and expertise lev-
els in a specific area. Two examples of these are illustrated
below and in Figures 1 and 2.
MULTI-LAYERED TARGET DRUGGABILITY ASSESS-
MENT VIEW
Druggability assessment allows users to examine a target’s
potential for drug discovery, identify key risks associated
with the pursuit of the target, and devise experiments to
address these risks. canSARblack provides this information
in a multi-layered approach to allow expert users to navi-
gate and examine the data in greater depth than was previ-
ously possible, while maintaining an understandable sum-
mary view for users with less experience in these areas.
Initially, a summary of all the information is provided on
the target (Figure 1A). This includes known drugs acting
on the target where available, together with a summary of
the level of structural characterisation of the protein with
the PDB structures coloured according to the existence of
druggable domains. The chemistry- and network-based as-
sessments described above are also provided. To improve
understanding, the target is benchmarked against other hu-
man proteins in each assessment. A meter-view provides a
high-level instant indication of the potential of this target.
To explore the information in detail, users can access the
next layer of structural annotation (Figure 1B). Here, the
user can navigate through images and ligandability scores
for each individual structure.
Moreover, canSAR’s druggability assessment utilizes a
large number of features in its predictive algorithm, in-
cluding volume, enclosure and additional features such as
hydrogen-bond donors, hydrophobic fraction etc. These
features are useful for expert users when examining novel
potential targets. We provide distributions, in the form of
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Figure 1. canSARblack target synopsis showing the navigation wheel and druggability assessment. (A) Target synopsis. Left hand panel displays the icons
representing key information on the target as well as a summary description of it. The icons are ticked green and coloured if the target meets certain criteria.
For example, if the target is a drug target; if it has a structurally ligandable cavity; if it has bioactive compounds etc. Hover-over of the icons provides the
user with the information on each. The right-hand panel provides the new navigation wheel. The user can navigate to key sections of information by clicking
on the appropriate sector in the wheel. Here the ligandability information is summarised. First, displaying drugs that are approved or under investigation
as well as links to chemical probes; second, summarizing the structurally characterised domains of the protein with a histogram showing the number of
available structures for that domain; and whether they contain ligandable cavities; third, the bottom layer provides the chemistry-based assessment and
network-based target likeness as a ‘meter’ showing how high the score is for the particular target. (B) Users can navigate into more detailed information
about the chains and domains and navigate through all individual structures. (C) Detailed view of individual structures and cavities. Users can explore
each of the key properties of these cavities and compare them to known drug target cavities such as kinases and BCL2. (D) Ligandable cavities at protein
interfaces can be examined in the same way. All images and raw data are downloadable.
violin plots, of how the target in question performs when
compared to bona-fide drug targets. Specifically, we pro-
vide comparator distributions for the druggable cavities
of highly druggable targets (kinases) and also more chal-
lenging protein–protein-interaction druggable targets rep-
resented by BCL2. These comparators allow users to gain
a rapid understanding of how their target compares with
typical drug targets.
Expert users can navigate to even deeper layers of in-
formation (Figure 1C). Here, users can examine each indi-
vidual cavity in detail, look for key residues (e.g. cysteines
for covalent interactions) and download all detailed data.
Where cavities are also identified in biological complexes,
users can explore these with the same level of detail through
the drop-downmenu and selecting one of the bioassemblies
(Figure 1D).
MULTI-LAYERED CANCER-ASSOCIATION VIEW
We developed a scoring system that associates a gene with a
particular cancer. The score takes into account all available
information from the clinic – such as drug approvals and
clinical trials where available; any aberrations or alteration
of the gene in patient data; and dependency on the gene in
cancer cell lines. The total score is used to summarize the
relevant cancers using a word map paradigm (Figure 2A).
Clicking on any one cancer type in the word map leads the
user to the details page that provides the key information in
each of these areas (Figure 2B and C).
A key advantage of the staging curation referred to above
is that users can now compare cancer gene expression data
against normal tissue from GTEx as well as progression
among pathological or clinical stages of the. For example,
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Figure 2. canSARblack target synopsis showing the cancer association summary. (A) word-map showing the association of each broad cancer type with
the target. The size of the name corresponds to the association score of the target with this cancer. (B) Where drug information is available, drug approval
and clinical trial information are listed. (C) Gene expression data and cell-line dependency are among the detailed information provided to help the user
examine the evidence of disease association. (D) Gene expression changes of AURKA with progression of clinical stage in adrenal carcinoma.
the expression of the kinase AURKA increases with the
more advanced stages of the cancer as shown in Figure 2D.
CONCLUDING REMARKS AND FUTURE DEVELOP-
MENT
Currently, key canSARblack functionality is accessed
through links in canSAR v4.0. canSAR will transfer to
the new canSARblack interface over the next calendar year
with regular updates to the site. We will enhance the data
in canSAR including unique-to-canSAR data through
abstraction of key literature on chemical probes; biological
activities; target engagement biomarkers; and drug com-
binations. Moreover, canSAR will contain new chemical
analysis pipelines to enable more sophisticated analysis and
interrogation of its chemistry data. Close links are provided
to a range of other key resources, including The Chemical
Probes Portal and Probe Miner for chemical probes (10)
and the Cancer Dependency Map (DepMap) resource that
connects tumour features with tumour dependencies (11)
(https://depmap.org). This will enable users to seamlessly
navigate between canSAR and DepMap for their targets
of interest. Moreover, canSAR drug and druggability
assessment algorithms will expand substantially to cover
biologics, immunotherapeutics and cryptic druggable sites.
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